On Tuesday, March 30, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

What Are Earnings, Net Income, And Earnings Per Share?

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Wall Street expects an EPS loss of $0.24 and sales around $3.82 million. In the same quarter last year, Pieris Pharmaceuticals reported EPS of $0.06 on revenue of $17.27 million.

Why Analyst Estimates And Earnings Surprises Are Important

The analyst consensus estimate would represent a 300.0% decrease in the company's earnings. Sales would have fallen 77.88% from the same quarter last year. Here is how the company's EPS has stacked up against analyst estimates in the past:

Stock Performance

Shares of Pieris Pharmaceuticals were trading at $2.6 as of March 26. Over the last 52-week period, shares are up 13.6%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Pieris Pharmaceuticals is scheduled to hold the call at 08:00:00 ET and can be accessed here.